NCT03252249

Duration of Dual Anti-Platelet Therapy (DUAL-ACS)

Duration of Dual Anti-Platelet Therapy in Acute Coronary Syndrome

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 5,094 (actual)
• Sponsor: University of Edinburgh · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Despite substantial evidence supporting the use of dual anti-platelet therapy in patients with acute coronary syndrome, there remains major uncertainty regarding the optimal duration of therapy. Recent evidence suggests that shorter durations of dual anti-platelet therapy are superior because the avoidance of atherothrombotic events is counterbalanced by the greater risks of excess major bleeding with apparent increases in all-cause mortality with longer durations. We here propose an international randomised controlled trial of 18,318 patients with type 1 myocardial infarction allocated to differing durations of dual anti-platelet therapy. We will use electronic health record linkage to track duration of therapy and clinical outcomes in a real-world, real-time, efficient and highly cost-effective trial. This has the potential to define treatment duration, settle a major outstanding international controversy, and influence modern cardiology practice across the world.

Conditions

• Acute Coronary Syndrome
• Coronary Artery Disease

Interventions

Type	Name	Description
OTHER	3 months dual anti-platelet therapy	Patients with acute coronary syndrome will be randomised to 3 months dual anti-platelet therapy.
OTHER	12 months dual anti-platelet therapy	Patients with acute coronary syndrome will be randomised to 12 months dual anti-platelet therapy.

Timeline

• Start date: 2018-12-11
• Primary completion: 2023-02-04
• Completion: 2023-02-04
• First posted: 2017-08-17
• Last updated: 2026-02-18
• Results posted: 2026-01-28

Locations

1 site across 1 country: United Kingdom